Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway

Oncotarget

Volumn 5, Issue 16, 2014, Pages 7081-7092

  McClurg, Urszula L ^a   Summerscales, Emma E ^a   Harle, Victoria J ^a   Gaughan, Luke ^a   Robson, Craig N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Akt; Androgen Receptor; PHLPP; PHLPPL; Prostate cancer; Uaf 1; Usp12; WDR20

Indexed keywords

ANDROGEN RECEPTOR; PHLPP PROTEIN; PHLPPL PROTEIN; PHOSPHATASE; PROTEIN; SERINE; SERINE 213; SERINE 791; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN; NUCLEAR PROTEIN; PHLPP1 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE B; UBIQUITIN THIOLESTERASE; USP12 PROTEIN, HUMAN;

ABLATION THERAPY; ANIMAL CELL; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DEPHOSPHORYLATION; DOWN REGULATION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; TUMOR SUPPRESSOR GENE; ANIMAL; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UBIQUITINATION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; HEK293 CELLS; HUMANS; MALE; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; UBIQUITIN THIOLESTERASE; UBIQUITINATION;

EID: 84907069900     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2162     Document Type: Article

References (38)

1. Culig Z. Role of the androgen receptor axis in prostate cancer. Urology. 2003; 62(5 Suppl 1):21-26.
2. Feldman BJ and Feldman D. The development of androgen- independent prostate cancer. Nature Reviews Cancer. 2001; 1(1):34-45.
3. Ryan CJ, Smith A, Lal P, Satagopan J, Reuter V, Scardino P, Gerald W and Scher HI. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression. Urology. 2006; 68(4):834-839.
4. Gaughan L, Logan IR, Neal DE and Robson CN. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Rese-arch. 2005; 33(1):13-26.
5. Lin HK, Wang L, Hu YC, Altuwaijri S and Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 2002; 21(15):4037-4048.
6. He B, Bai S, Hnat AT, Kalman RI, Minges JT, Patterson C and Wilson EM. An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). The Journal of Biological Chemistry. 2004; 279(29):30643-30653.
7. Cardozo CP, Michaud C, Ost MC, Fliss AE, Yang E, Patterson C, Hall SJ and Caplan AJ. C-terminal Hsp- interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Archives of Biochemistry and Biophysics. 2003; 410(1):134-140.
8. Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Kong X, Melamed J, Fang S, Xiao Z, Veenstra TD and Qiu Y. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell. 2009; 15(4):270-282.
9. Li H, Xu LL, Masuda K, Raymundo E, McLeod DG, Dobi A and Srivastava S. A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. The Journal of Biological Chemistry. 2008; 283(43):28988-28995.
10. Shenoy SK, Xiao K, Venkataramanan V, Snyder PM, Freedman NJ and Weissman AM. Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the beta2-adrenergic receptor. The Journal of Biological Chemistry. 2008; 283(32):22166-22176.
11. Dirac AM and Bernards R. The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Molecular Cancer Research. 2010; 8(6):844-854.
12. Faus H, Meyer HA, Huber M, Bahr I and Haendler B. The ubiquitin-specific protease USP10 modulates androgen receptor function. Molecular and Cellular Endocrinology. 2005; 245(1-2):138-146.
13. Burska UL, Harle VJ, Coffey K, Darby S, Ramsey H, O'Neill D, Logan IR, Gaughan L and Robson CN. Deubiquitinating enzyme Usp12 is a novel co-activator of the Androgen Receptor. The Journal of Biological Chemistry. 2013; 288(45):32641-32650.
14. Sarker D, Reid AH, Yap TA and de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clinical Cancer Research. 2009; 15(15):4799-4805.
15. Assinder SJ, Dong Q, Kovacevic Z and Richardson DR. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. The Biochemical Journal. 2009; 417(2):411-421.
16. Lin HK, Yeh S, Kang HY and Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(13):7200-7205.
17. Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, Fischbeck KH, Howell BW and Pennuto M. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Human Molecular Genetics. 2007; 16(13):1593-1603.
18. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH and Hung MC. HER-2/neu promotes androgen- independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Resea-rch. 2000; 60(24):6841-6845.
19. Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ and Logan SK. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene. 2013; 32(34):3992-4000.
20. McCall P, Gemmell LK, Mukherjee R, Bartlett JMS and Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer. 2008; 98(6):1094-1101.
21. Brognard J, Sierecki E, Gao T and Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Molecular Cell. 2007; 25(6):917-931.
22. O'Neill AK, Niederst MJ and Newton AC. Suppression of survival signalling pathways by the phosphatase PHLPP. FEBS Journal. 2013; 280(2):572-583.
23. Li X, Liu J and Gao Tbeta- TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Molecular Cell Biology. 2009; 29(23):6192-6205.
24. Li X, Stevens PD, Yang H, Gulhati P, Wang W, Evers BM and Gao T. The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer. Oncogene. 2013; 32(4):471-478.
25. Zhiqiang Z, Qinghui Y, Yongqiang Z, Jian Z, Xin Z, Haiying M and Yuepeng G. USP1 regulates AKT phosphorylation by modulating the stability of PHLPP1 in lung cancer cells. Journal of Cancer Research and Clinical Oncology. 2012; 138(7):1231-1238.
26. Gangula NR and Maddika S. WD Repeat Protein WDR48 in Complex with Deubiquitinase USP12 Suppresses Akt-dependent Cell Survival Signaling by Stabilizing PH Domain Leucine-rich Repeat Protein Phosphatase 1 (PHLPP1). The Journal of Biological Chemistry. 2013; 288(48):34545-34554.
27. Sowa ME, Bennett EJ, Gygi SP and Harper JW. Defining the Human Deubiquitinating Enzyme Interaction Landscape. Cell. 2009; 138(2):389-403.
28. Kee Y, Yang K, Cohn MA, Haas W, Gygi SP and D'Andrea AD. WDR20 regulates activity of the USP12 x UAF1 deubiquitinating enzyme complex. The Journal of Biological Chemistry. 2010; 285(15):11252-11257.
29. Faesen Alex C, Luna-Vargas Mark PA, Geurink Paul P, Clerici M, Merkx R, van Dijk Willem J, Hameed Dharjath S, El Oualid F, Ovaa H and Sixma Titia K. The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chemistry and Biology. 2011; 18(12):1550-1561.
30. Coffey K and Robson CN. Regulation of the androgen receptor by post-translational modifications. The Journal of Endocrinology. 2012; 215(2):221-237.
31. Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G and Georgescu MM. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene. 2012; 31(10):1264-1274.
32. Draker R, Sarcinella E and Cheung P. USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation. Nucleic Acids Research. 2011; 39(9):3529-3542.
33. Chen J, Dexheimer TS, Ai Y, Liang Q, Villamil MA, Inglese J, Maloney DJ, Jadhav A, Simeonov A and Zhuang Z. Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chemistry and Biology. 2011; 18(11):1390-1400.
34. Liang Q, Dexheimer TS, Zhang P, Rosenthal AS, Villamil MA, You C, Zhang Q, Chen J, Ott CA, Sun H, Luci DK, Yuan B, Simeonov A, Jadhav A, Xiao H and Wang Y. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nature Chemical Biology. 2014.
35. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE and Robson CN. Tip60 is a nuclear hormone receptor coactivator. The Journal of Biological Chemistry. 1999; 274(25):17599-17604.
36. Cohn MA, Kee Y, Haas W, Gygi SP and D'Andrea AD. UAF1 is a subunit of multiple deubiquitinating enzyme complexes. The Journal of Biological 2009; 284(8):5343-5351.
37. Gao T, Furnari F and Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Molecular Cell. 2005; 18(1):13-24.
38. Lu S, Tsai SY and Tsai MJ. Molecular mechanisms of androgen- independent growth of human prostate cancer LNCaP-AI cells. Endocrinology. 1999; 140(11): 5054-5059.